Zynlonta is a prescription drug used to treat certain types of large B-cell lymphoma. Learn about the common, mild, and serious side effects it can cause and how to manage them.

Zynlonta infusions are usually given at a hospital, doctor’s office, infusion center, or clinic. They’re prepared and administered by a healthcare professional as an IV infusion.

Zynlonta’s dosage amount may vary depending on your cancer treatment schedule. Zynlonta is typically given in cycles that last 3 weeks. It’s given on the first day of each cycle.

Zynlonta can cause side effects that range from mild to serious. Examples include tiredness, nausea, and diarrhea. Specifically, Zynlonta is used to treat the following kinds of B-cell lymphoma in ...

LOTIS-2 updated results demonstrate durable responses of ZYNLONTA™ with median duration of response of 13.4 months in heavily pre-treated patients with relapsed or refractory DLBCL. LAUSANNE ...

Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "ZYNLONTA Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering.This report provides ...

ZYNLONTA® is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload.

ZYNLONTA was generally well tolerated and safety was consistent with known profile . LAUSANNE, Switzerland, June 16, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage ...

Dose escalation in Phase 1b trial completed with no dose-limiting toxicities, no or low-grade cytokine release syndrome and no immune effector cell-associated neurotoxicity syndrome across all ...

- ZYNLONTA is the first and only CD19-targeted ADC approved as a single-agent treatment for adult patients with r/r DLBCL LAUSANNE, Switzerland--(BUSINESS WIRE)-- ADC Therapeutics SA (NYSE: ADCT ...

ZYNLONTA was generally well tolerated with adverse events consistent with its known safety profile. Most adverse events were grade 1 or 2, though grade 3 and 4 events occurred in 16 and 2 patients ...

3Q 2023 ZYNLONTA ® 1 net sales of $14.3 million reflect disruption following restructuring of commercial organization, increased competition and higher gross-to-net deductions Operating expenses ...